Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering

$2 million upfront with up to additional $4 million of potential aggregate gross proceeds upon the exercise in full of warrants NEW YORK, NY, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it has entered into definitive agreements for the purchase and sale of 1,000,000 Class A ordinary shares at a purchase price of $2.00 per share in a registered ...